scholarly journals Upadacitinib Was Efficacious and Well Tolerated Over 30 Months in Patients with Crohn’s Disease in the CELEST Extension Study

2021 ◽  
Author(s):  
Geert D’Haens ◽  
Julian Panés ◽  
Edouard Louis ◽  
Ana Lacerda ◽  
Qian Zhou ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extension Study

scholarly journals OP031 Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S18-S19
Author(s):  
J. Panés ◽  
G.R. D'Haens ◽  
P.D.R. Higgins ◽  
L. Mele ◽  
M. Moscariello ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extension Study ◽  
Phase 2 ◽  
Open Label

Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study

2017 ◽  
Vol 152 (5) ◽  
pp. S601 ◽  
Author(s):  
Severine Vermeire ◽  
Edward V. Loftus ◽  
Jean Frederic Colombel ◽  
Brian G. Feagan ◽  
William J. Sandborn ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Cumulative Exposure ◽  
Extension Study ◽  
Open Label ◽  
Open Label Extension

scholarly journals Long-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension study

2019 ◽  
Vol 49 (3) ◽  
pp. 265-276 ◽  
Author(s):  
Julián Panés ◽  
Geert R. D’Haens ◽  
Peter D. R. Higgins ◽  
Linda Mele ◽  
Michele Moscariello ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Extension Study ◽  
Phase 2 ◽  
Open Label
Sign in / Sign up

Export Citation Format

Share Document